The bispecific PD-1×LAG-3 molecule Tebotelimab showed safety and effectiveness in advanced cancer, generating responses in various solid tumors and LAG-3+ non-Hodgkin lymphomas, even with margetuximab.61 This evidence concerns the gene LAG3 and cancer.